Pharmacokinetics and pharmacodynamics of alirocumab in patients with autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function or ApoB loss-of-function mutations

被引：0

作者：

Hopkins, P. N. ^{[1
]}

Krempf, M. ^{[2
]}

Bruckert, E. ^{[3
]}

Luc, G. ^{[4
]}

Donahue, S. ^{[5
]}

Yang, F. ^{[5
]}

Zhang, Y. ^{[5
]}

Dicioccio, A. T. ^{[5
]}

机构：

[1] Univ Utah, Sch Med, Salt Lake City, UT USA

[2] CHU Nantes, Hop Nord Laennec, St Herblain, France

[3] Hosp Pitie Salpetriere, Paris, France

[4] Univ Lille 2, Lille, France

[5] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

来源：

EUROPEAN HEART JOURNAL | 2018年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

352

引用

页码：49 / 49

页数：1

共 50 条

[31] Familial Hypercholesterolemia and Atherosclerosis in Cloned Minipigs Created by DNA Transposition of a Human PCSK9 Gain-of-Function Mutant
Al-Mashhadi, Rozh H.
Sorensen, Charlotte B.
Kragh, Peter M.
Christoffersen, Christina
Mortensen, Martin B.
Tolbod, Lars P.
Thim, Troels
Du, Yutao
Li, Juan
Liu, Ying
Moldt, Brian
Schmidt, Mette
Vajta, Gabor
Larsen, Torben
Purup, Stig
Bolund, Lars
Nielsen, Lars B.
Callesen, Henrik
Falk, Erling
Mikkelsen, Jacob Giehm
Bentzon, Jacob F.
SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (166)
[32] Association of PCSK9 Loss-of-Function Variants With Risk of Heart Failure
Trudso, Linea C. C.
Ghouse, Jonas
Ahlberg, Gustav
Bundgaard, Henning
Olesen, Morten S. S.
JAMA CARDIOLOGY, 2023, 8 (02) : 159 - 166
[33] Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9
Ouguerram, K
Chetiveaux, M
Zair, Y
Costet, P
Abifadel, M
Varret, M
Boileau, C
Magot, T
Krempf, M
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (08) : 1448 - 1453
[34] Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind
Boisson, Bertrand
Quartier, Pierre
Casanova, Jean-Laurent
CURRENT OPINION IN IMMUNOLOGY, 2015, 32 : 90 - 105
[35] Gain-of-function mutations in TRPV4 cause autosomal dominant brachyolmia
Matthew J Rock
Jean Prenen
Vincent A Funari
Tara L Funari
Barry Merriman
Stanley F Nelson
Ralph S Lachman
William R Wilcox
Soraya Reyno
Roberto Quadrelli
Alicia Vaglio
Grzegorz Owsianik
Annelies Janssens
Thomas Voets
Shiro Ikegawa
Toshiro Nagai
David L Rimoin
Bernd Nilius
Daniel H Cohn
Nature Genetics, 2008, 40 : 999 - 1003
[36] Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding
Sarkar, Samantha K.
Matyas, Angela
Asikhia, Ikhuosho
Hu, Zhenkun
Golder, Mia
Beehler, Kaitlyn
Kosenko, Tanja
Lagace, Thomas A.
FRONTIERS IN PHYSIOLOGY, 2022, 13
[37] JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences
Nils Ott
Laura Faletti
Maximilian Heeg
Virginia Andreani
Bodo Grimbacher
Journal of Clinical Immunology, 2023, 43 : 1326 - 1359
[38] Gain-of-function mutations in TRPV4 cause autosomal dominant brachyolmia
Rock, Matthew J.
Prenen, Jean
Funari, Vincent A.
Funari, Tara L.
Merriman, Barry
Nelson, Stanley F.
Lachman, Ralph S.
Wilcox, William R.
Reyno, Soraya
Quadrelli, Roberto
Vaglio, Alicia
Owsianik, Grzegorz
Janssens, Annelies
Voets, Thomas
Ikegawa, Shiro
Nagai, Toshiro
Rimoin, David L.
Nilius, Bernd
Cohn, Daniel H.
NATURE GENETICS, 2008, 40 (08) : 999 - 1003
[39] JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences
Ott, Nils
Faletti, Laura
Heeg, Maximilian
Andreani, Virginia
Grimbacher, Bodo
JOURNAL OF CLINICAL IMMUNOLOGY, 2023, 43 (06) : 1326 - 1359
[40] Loss- and Gain-of-function PCSK9 Variants CLEAVAGE SPECIFICITY, DOMINANT NEGATIVE EFFECTS, AND LOW DENSITY LIPOPROTEIN RECEPTOR (LDLR) DEGRADATION
Benjannet, Suzanne
Hamelin, Josee
Chretien, Michel
Seidah, Nabil G.
JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (40) : 33745 - 33755

← 1 2 3 4 5 →